RBC Capital Remains a Buy on Surgery Partners (SGRY)
In a report released today, Frank Morgan from RBC Capital maintained a Buy rating on Surgery Partners (SGRY), with a price target of $14.00. The company’s shares closed last Monday at $9.80.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 9.9% and a 61.7% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care, Genesis Healthcare, and Acadia Healthcare.
Surgery Partners has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
See today’s analyst top recommended stocks >>
Based on Surgery Partners’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $517 million and GAAP net loss of $19.2 million. In comparison, last year the company earned revenue of $491 million and had a GAAP net loss of $148 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.